000 05388nam a22004095c 4500
999 _c7611
_d7611
001 7611
003 ES-MaUEC
005 20200716092427.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 190401s2019 gw a s |||| 0|eng d
020 _a9783030117481
024 7 _a10.1007/978-3-030-11748-1
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRM301.25
_b.T73 2019 EB
245 0 0 _aTranslational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease.
_bA Focus on Early Phase Clinical Drug Development
_cedited by Andrew J. Krentz, Christian Weyer, Marcus Hompesch.
250 _a2nd ed. 2019.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2019.
300 _a1 recurso en línea (XI, 556 páginas)
_b115 ilustraciones, 59 ilustraciones a color
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 0 _aMedicine (Springer-11650)
505 0 _aPart 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS – CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations.
520 3 _aThis book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
988 _aPrimersemestre_2019_Medicine
700 1 _aKrentz, Andrew J.
_eeditor literario
_4http://id.loc.gov/vocabulary/relators/edt
_994432
700 1 _aWeyer, Christian.
_eeditor literario
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aHompesch, Marcus.
_eeditor literario
_4http://id.loc.gov/vocabulary/relators/edt
_994434
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9783030117474
776 0 8 _iPrinted edition:
_z9783030117498
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-11748-1
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0
_zSI